Compare Citius Pharmaceuticals Inc (CTXR) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Banco Santander SA trades at $13.69 (market cap $195.40B). The key difference: Banco Santander SA is far larger — about 13347× Citius Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 2.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SAN | |
|---|---|---|
Market Cap | $14.64M | $195.40B |
Sector | Health | Financials |
52-Week High | $1.82 | $14.37 |
52-Week Low | $0.53 | $8.31 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Banco Santander (SAN) trades at $13.66, down 1.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.4144, beating expectations, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value. The stock shows a P/E of 13.57 and P/B of 1.62, indicating reasonable valuation relative to peers.
The outlook for SAN is positive, supported by record profitability, strategic acquisitions, and cost-saving measures. However, risks include declining cash flows, regulatory scrutiny in Spain, and macroeconomic pressures on loan growth. Analyst consensus is bullish with 64% buy ratings, but investors should monitor execution on efficiency targets and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
